The preceeding paper described the origin and evolution of the pathology portion of carcinogen bioassays conducted under the direction of the National Cancer Institute (NCi) and subsequently by the National Toxicology Program (NTP). Review of 277 studies conducted under the NCI/NTP protocol suggested that the present number of tissues/organ5 was in excess to what is needed to detect if a given chemical induces cancer in rats and/or mice. In addition, the ability of the previous protocol to detect and define non-neoplastic chemically related lesions may be inadequate. This paper describes alternative pathology protocols and proposes one that will answer the question of a given chemicals' carcinogenic potential while at the same time give superior information on nonneoplastic chemical related pathology. In addition this protocol will reduce the volume of histopathology required in most studies by over 50%.
INTRODUCTION
The preceeding paper described the origin (Sontag, et al., 1976) and evolution of the pathology portion of carcinogen bioassays conducted under the direction of the National Cancer Institute (NCI) and subsequently by the National Toxicology Program (NTP). Historically, the pathology workload encompassed in a typical NTP bioassay consisted of post mortem examination of all 600 animals (300 rats and 300 mice) followed by histopathologic examination of 42-44 sections of 31-33 organs from each animal. This required the microscopic examination of 25,000-26,000 sections per test chemical and represented a minimum of one-half pathologist man-year and a significant investment on the part of the supporting histology laboratory. Current protocols often include a third exposure level which will increase the pathology workload by 33%.
The results of the preceeding paper showed that while a relatively large variety of 28 * Presented at the Second International Symposium of the Society of Toxicologic Pathologists, Session I: "Protocols Past and Present", May 9-11.1983. Arlington. Virginia.
This Symposium section will be continued in Volume 11. Number 2,1983. tissues and organs have been used to incriminate various chemicals as animal carcinogens, 12 of these 28 were identified only as a result of abnormalities observed at necropsy. In other words, neoplasms in these tissues would not have been identified based on random sampling of the affected tissues. Neoplasms in 1 2 of the remaining 16 tissues and organs were also recognized primarily at necropsy, although microscopic examination was required for definitive diagnoses and an accurate incidence. It was therefore concluded that the present number of tissues and organs was in excess to what is needed to detect if a given chemical induces cancer in rats or mice.
The ability of the previous NTP protocol to detect and define non-neoplastic chemically related lesions was also examined. Numerous tissues and organs showed direct and indirect (exacerbation of aging and spontaneous disease) toxic lesions. Also, many of these tissues and organs showing lesions would not be grossly recognized at necropsy. Therefore, it was felt that the previous protocol which called for the routine examination of 31-33 tissues was required to ascertain the toxicopathology induced by the test chemical. The TOXICOLOGIC PATHOLOGY NTP has recently incorporated a 15-month interim evaluation into its two-year protocol for the purpose of detecting chronic toxicity. This includes the addition of 10 animals/ sex/dose in both species of rodents. These animals will receive a necropsy examination and histopathology will be conducted using the "inverse pyramid" approach. Evaluations at earlier time points for the purpose of following the progression of toxic lesions are used on a case by case basis.
The following represents an attempt to examine alternative procedures to the present protocol which would maintain or enhance the ability to detect neoplasms as well as defining non-neoplastic disease induced by chemicals, yet require a smaller pathology workload.
MATERIALS AND METHODS
Various alternatives to the current pathology protocol portion of the NTP carcinogen bioassay were investigated. The alternatives were compared with the current protocol using the NTP historical data base. Several assumptions must be made prior to evaluation of the alternatives. They are as follows:
1. Number of animals per sex/dose re- 3. All animals from all dose groups will receive a complete post mortem examination as defined in Table 1 . 4. A "complete" set of tissues (Table 2) will be preserved in a suitable fixative for possible histopathologic examination. 5. A "complete" histopathologic examination is defined as microscopic examination of the 31-33 tissues/organs listed in Table 2 . 6. A typical study will have 6-8 tissues/ organs/animal showing grossly visible lesions (or a target organ effect).
7. Males and females are examined in the same manner. 8. Each sex/species within a given study is evaluated independently. 9. The same pathologist will examine all of the histologic sections of a given animal species. 10. A 15-month evaluation for the purpose of defining chronic toxicity is part of the protocol. The alternatives chosen for evaluation in this presentation were as follows: Option 1-Inverse Pyramid 1. "Complete" (31-33 tissues/organs) histopathologic examination of all animals from the highest dose and control groups. 2. Histopathologic examination of tissues and organs at lower doses where chemically related neoplastic or non-neoplastic effects were identified in the high dose animals or in which there were grossly visible lesions. 3. If survival in the high dose is reduced because of toxicity (unrelated to neoplasia), "complete" histopathology is conducted on all animals in the next high dose in addition to the high dose. Target organs and gross lesions are examined in lower dose group(s) if they are part of the study. Option 2-Selective Inverse Pyramid 1. Histopathologic examination from all high dose and control animals of a subset "core" of 16 to 18 tissues previously associated with neoplasia ( Table 3) or suspect target organs based on subchronic studies, or on previous studies with the chemical or related chemicals based on clinicopathological observations. 2. Histopathologic examination of tissues and organs at lower doses where chemically related neoplastic or non-neoplastic effects (target organs) were identified in the high dose group. 3. Histopathologic examination of all gross abnormalities in all animals. 4. If survival in the high dose is reduced because of toxicity (unrelated to neoplasia), histopathology will be conducted on the "core" tissues (Table 3) in the next high dose group as well as the high dose group animals. Target organs will be examined in lower dose(s) groups.
Each option was evaluated as to its impact on: pathology workload; ability to answer the essential questions of neoplastic and non-neoplastic chemical effects; and the level of management required to implement.
RESULTS
For comparative purposes the options were evaluated against a current protocol using 50 animals/sex/dose (2 exposed and 1 control)/ species (F344 rats and B6C3F1 mice for a total of 600 animals. It is assumed that "complete" histopathology will require the examination of 43 sections and that there are an average of 6 target organs and/or gross lesions per animal/sex/species observed in lower dose groups. The number of sections and impact on workload is shown in Table 4 . In terms of impact on scientific data, the inverse pyramid option will provide a complete set of pathology data on the high dose and control groups and will allow the tracking of target organ neoplasms and toxic lesions to lower doses. Positive and negative trends will be identified. The true incidence of neoplasms and aging lesions which are not chemically related will not be determined for the lower dose groups. Concerning the impact on management, a minimal number of decision points are required. The results of the 15 month interim evaluation should be known prior to the termination of the two-year study to enhance correct identification of target organs. Chemically related increases or decreases in the incidence of neoplasms in the high dose groups will need to be identified.
The histopathology Workload of the Selective Inverse Pyramid is shown in Table 5 . TOXICOLOGIC PATHOLOGY Analysis of the impact on scientific data shows that, this modification will provide an accurate incidence of neoplasms and nonneoplastic lesions in those organs designated for review. Positive and negative trends would be identified. The historical data base on two year old control animals will be narrower in scope because fewer tissues will be examined.
The impact on management shows relatively few decision points required to implement this modification. Target organs (toxic and neoplastic) in the high dose groups will need to be identified. The "essential" list of tissues/organs may need to be enlarged based on the'results of subchronic studies, on the 15-month interim evaluation, on clinicopathologic information, and on results found in the literature.
DISCUSSION
The results of this investigation show that there are scientifically valid alternate approaches to the histopathologic review of carcinogen bioassays to that currently in use by the NTP (Sontag et a] ., 1976). The current protocols or guidelines issued by governmen- tal agencies, nations, international organizations and manufacturing associations vary to some degree on the amount of histopathology required, but most of these guidelines ( Table  6) use an approach similar to the "Inverse Pyramid." All protocols cited require the post mortem examination of all study animals. When viewed in their totality, the carcinogenesis bioassays conducted by industry and governmental agencies represent a vast amount of resources dedicated to the elucidation of the carcinogenic potential of innumerable drugs and chemicals. Obviously, any modification in these protocols that would reduce the histopathologic workload would represent a significant savings in time, effort and capital.
The ideal modification is one which would retain the tests ability to: 1. Detect an increased incidence of neoplasms; 2. Detect unusual or unique neoplasms; 3. Detect reduced time to neoplasm; 4. Detect direct and indirect toxic lesions; 5. Detect a chemically related increased incidence of/or severity of aging lesions. If the modified protocol cannot address these objectives as well or better than the current protocol, the value of the resulting scientific data would be compromised and incorporation of the alternative approach may not be justified. However, it would also be a mistake not to recognize the fact that chronic carcinogenesis studies involve the use of a complex test system (animals), that these studies may have certain inherent flaws in terms of reproducibility, sensitivity and the ability to interpret observations is some times difficult. In other words, it is a mistake to ask the test method to answer more questions than it is capable of.
The proposed modification should also save enough time and effort to warrant its use. Obviously the greater the amount of reduced histopathology, the greater the savings in terms of time and money. Since the cost of pathology in current chronic studies supported by the NTP represents 3 5 4 5 % ($175,000-$225,000) of the total (approximately $500,000 for a typical feed study), even a 20% savings represents a significant amount of resources. Such savings are also more im~ortant than just in terms of money. Pathologists competent in rodent pathology are in a relatively limited supply. Any method which could better utilize this limited national resource is justified, if other scientific and managerial considerations are met.
The final criteria that must be addressed by any modification is the ease of implementation and extent of decision making required to carry it out. If a modification cannot be implemented in a variety of laboratories of differing abilities, it looses a certain amount of its value. Both modifications described here require decisions on the part of the responsible pathologist. Most of the decisions involve the choice of what tissues/organs need to be examined at lower doses. While statistical evaluations are the basis for many of these decisions, they cannot be used in ~s o~~t i o n .
For instance, any lesion (neoplastic or non-neoplastic) in the high dose animals which in the judgment of the pathologist may in any way be associated with the chemical, needs to be evaluated in lower dose animals. This should entail the elucidation of negative as well as positive trends.
Management as well as scientific abilities will be tested by either option. Interpretation of data that are presently considered usually at the end of a study will need to be addressed at an earlier point. For instance, chronic toxic lesions should be identified prior to evaluation of the 2-year study animals. This is particularly important for ~mplementation of the Selective Inverse Pyramid approach. The degree of efficiency of any modification will be in direct proportion to scientific management abilities of the responsible pathologist.
It is apparent after reviewing the alternatives described in this paper as well as the current protocol, that there is one essential prerequisite that is required for any of the approaches to succeed; a thorough post mortem examination. A thorough necropsy entails much more than the collection of tissues for subsequent histopathologic examination.
If a given lesion is not recognized at necropsy and therefore not saved or fixed, it is lost forever. A pathologist has only one chance to perform the necropsy of a given animal and to recognize abnor~alities: in contrast to stained sections which can be re-evaluated innumerable times. It is for this reason that the NTP insists upon a professional pathologist to conduct or directly supervise the post mortem examinations. In addition, it is preferable that the pathologist evaluating the histopathology be the same person who conducted the necropsy. A better correlation of gross and microscopic pathology is attained in this way. TOXICOLOGIC PATHOLOGY Another question that needs to be discussed prior to evaluating the merits of any modification to the existing pathology protocol(s) is "Why do we currently require the examination of a complete set of 31 to 33 tissues and organs?" The earliest chemical carcinogen bioassays were directed at determining the cancer causingpotential of a given chemical at a specific site, i.e. skin (Yamagiwa and Ichikawa, 1918) or lung (Murphy and Strum, 1925) . It was soon recognized that chemicals administered at a given site could cause cancer at distant locations in the body, often in unsuspected locations. Additionally, one often found that the induced neoplasm was not unique in its morphology but rather was important because of its increased incidence compared to the controls or because it occurred at an earlier than expected time in the life of the test animal.
It soon became apparent that the background incidence of a given neoplasm or other lesion was necessary information for interpreting potential chemical effects. Therefore it became essential to examine as many tissues or organs as possible from control and treated animals to make legitimate conclusions. This view or approach has been the state-of-the-art since the decade of the 1960's. Because of this past approach, we now have an extensive data base upon which to consider more efficient methodologies. In this regard the NTP data base comprising over 250 carcinogenesis bioassays represents a vast amount of information upon which to draw for evaluating alternative approaches.
With the above background in mind the various modifications outlined in this presentation were compared.
Option 1 (Inverse Pyramid) is straightforward, requires a minimum amount of scientific judgement to implement, should be easy to manage and should yield an equivalent amount of scientific information as the current protocol. It also has an added benefit that it has been used previously in NTP subchronic studies and in other government and industrial laboratories where it has withstood the test of time and rigorous peer review. This modification would provide control animal data for all tissues/organs and allow for continual updating of the historical data base. While concurrent control data is the most valuable for comparative purposes, inconsistent results can often be identified by comparisons with historical data. The only drawback of this modification is that the savings in pathology effort, while substantial (21%), are relatively small compared to the other modification evaluated. The savings would be greater in studies involving more than two dose levels.
Option 2 (Selective Inverse Pyramid) is also straightforward but requires a greater level of decision making on the part of the responsible pathologist. While important in Option 1, the pathologist will need to be particularly cognizant in Option 2 of the results of the subchronic studies, the 15-month interim evaluation, the clinicopathologic findings in the subject study and what is known about the toxicopathology of this chemical or similar chemicals in order to add tissues and organs to the core list.
The selective inverse pyramid approach should yield an equivalent amount of and quality of pathology data concerning the incidence of neoplasms compared to the current protocol. The presence of direct and indirect toxic non-neoplastic lesions would be evaluated based on the results of the 15month interim evaluation.
This modification would result in the greatest savings (61%) in histopathology of the two modifications described. The savings would be even greater in protocols involving more than two dose levels.
A continual updating of the historical data base for the core tissues would be possible with the selective inverse pyramid approach. It would allow for comparison of pathology data to that developed in the study laboratory as well as Program wide data. However, over a period of time the data base for noncore tissues would be diminished.
In deciding which of the modifications would be superior to the present protocol, the basic premise needs to be reiterated. Any modification must retain an equivalent power to ascertain an altered rate of incidence of neoplasia and define any chemically related non-neoplastic disease. At the same time it should, if possible, add to the scientific data .base. The more savings of pathology effort the better. Finally, the modification needs to be straightforward enough to be clearly understood and easily implemented in a wide variety of laboratories.
The foregoing discussion suggests that either modification is justified, and both are superior to the current protocol in terms of savings of pathology workload. Further, the Selective Inverse Pyramid should be considered for use by the NTP for the same reason.
The ability to detect neoplasms in the core list of essential tissues would be equivalent to the present protocol. It should be remembered that all grossly observed lesions will be examined microscopically using this scheme. For neoplasms to be missed at other sites they would have to be unrecognizable at necropsy. The odds of this happening are remote, requiring the submacroscopic involvement of a tissue or organ that has never before been shown to respond to chemical neoplasia either in the NCI/NTP bioassays or in those summarized by the International Agency for Research on Cancer (1980) . The involved tissue or organ would also have to be recognized only as the result of routine microscopic examination of randomly selected tissues. The biological sensitivity of the bioassay test system must be infinitely less than the proposed risk of not sampling all of the tissues/organs presently examined. Additionally, the responsible pathologist may add any tissue or organ to the list that could be useful in evaluating the study.
While this modification was designed with the NTP mission in mind, it should work equally well with other strains of mice and rats, and possibly other species. All that is needed is a thorough knowledge of the background incidence of lesions in that particular species so that tissues and organs may be added or deleted as needed from the core list of essential tissues.
The standard "Inverse Pyramid" approach is certainly as effective as the one proposed. The only reason for not choosing it as the approach of choice is that the pathology savings in the "Selective Inverse Pyramid" modification are significantly greater. In situations where the data base is limited, this may be a superior approach, at least until such a One caveat that must be considered in implementing either the "Inverse Pyramid" or "Selected Inverse Pyramid" modification is when the high dose animals show decreased survival that is not related to neoplasia (toxic related death). In such a case the next high dose group (low dose group in %dose studies) becomes the baseline dose group for comparison to the control group. However, the tissues from the high dose group are also examined in the same way as called for in the .base is established. respective modifications. While the amount of savings in this instance would be less, the modification is still worthwhile because the decreased survival might be present in only one species or in one sex of one of the species. This caveat is not unique and is standard operating procedure in many protocols (Environmental Protection Agency, 1982; Food and Drug Administration, 1982;  Organization for Economic Cooperation and Development, 1981) .
The value of any of either of these modifications is enhanced if the resulting data is subjected to peer review, such as that performed in the NTP Quality Assurance and Pathology Working Group evaluations (Maronpot and Boorman, 1983) . TOXICOLOGIC PATHOLOGY D~SCUSSION OF THE PAPER DR. DIENER: I wish to compliment you on your nice presentation. I'd like to come back to what you said in the beginning that everything has its circadian rhythms and looking back historically, I think we are going back to what we used to do in the '60's for FDA, because they were advocating 18 month or 24 month carcinogenicity studies and a combination of toxicity which could be ascertained at 1 2 months. I think your program here would certainly help the NCI protocol because it offers one more dose and it has some clinical chemistry parameters which often are very helpful. But, I wonder if interpretation of the deaths will add something which will end up in statistics when actually it may be a big guessing game because that cause of death depends to a great extent upon how good the pathologist is and how many studies he has done. DR. MC CONNELL: Yes, I would agree with your point, but I would like to modify one part. In terms of "we're going back to where we were"-I think we can afford to go back to where we were because we have now a great deal more data upon which to base this decision. In the 60's we didn't have the data from 287 bioassays to authoritatively say that we really don't need to look at all those tissues. I'm not criticizing the earlier protocols. I think their design was very good for that time and it provided us with a great deal of information upon which to build. Now we can, because of our experience, possibly back off a little bit. In response to your question concerning the cause of death-there have been some discussions in Europe (R. Pet0 et a]., IARC, 1980) where the pathologists were very critical of being asked to determine the cause of death and, in fact, said it couldn't be done. When they were pushed they were able to come up with the cause of death in about 60-70% of the early deaths. Obviously, in terms of life-table analysis, the cause of death is primarily important in regard to neoplasms. One approach that a person could take, for example, is to simply say if you observe a hepatocellular carcinoma of the liver-that a priori it is a lethal neoplasm no matter if it is large or small. Another approach is for the pathologist to make an interpretation as to whether the hepatocellular neoplasm was lethal in this particular case or at least if it contributed to the demise of that animal. With some tumors such an interpretation is going to be easier than with others. If I see Fischer rat leukemia in an animal, I don't care what other lesions were present. I'm still going to call that the probable cause of death even if there is a large mammary tumor present. Establishing the cause of death is going to be a difficult proposition. However I think we can do more than we are doing now. Right now, we are doing nothing.
DR. KIRCHER: Gene, you mentioned that you are going to settle for 24 months and stay at that, that you thought most people were going that route. Did you base that on a survey or are you just taking a guess at what most people are doing?
DR. MC CONNELL: It is based on a survey of guidelines, especially European, and our own work. We have a paper that's being put together right now (H. A. Solleveld, et a]., submitted to JNCI). We recently completed a 5000 rat study on the effects of oral asbestos. The animals in this study were allowed to live until ten per cent of the animals were still alive. It was an excellently conducted study with good survival. We've shown that after 24 months, the incidence of some of the more common neoplasms increases dramatically. With other neoplasms the incidence does not increase very much after 24 months. However, there's enough of the ones that increase in incidence, to indicate that 24 months seems to be a good time to terminate a study. To substantiate this point let's say you have an incidence of a tumor at 24 months of 10% in the controls and 25% in the treated animals. Statistically and biologically this would be a treatment related effect. In contrast if the control and treated groups are 50% and 75% respectively, there are no differences statistically. In summary if you carry these studies for too long, where the control incidence becomes high, you'll never be able to show whether a chemical decreased the latency of a neoplasm or increased its incidence. DR. KIRCHER: What about mice? Eighteen months?
DR. MC CONNELL: The same is true for mice. Some protocols used to propose eighteen months, but with our particular strain of mouse (B6C3Fl) we have good survival at 24 months (75-80%). Therefore we feel that it's certainly reasonable to carry that species of mouse to 24 months rather than to 18. We don't have the same data for other strains of mice. In regard to carrying mice beyond 24 months, I would envision that a rapid increase in certain types of neoplasms would occur. If anybody wants to do a 5000 mouse study to get this information, it certainly would be worthwhile.
DR. WEINBER~ER: I would like to say that I think it's very important to look at all of the animals that die early in the study whether for toxicity or carcinogenicity because, in addition to the reasons that you gave for looking at them, these could represent animals that are very sensitive to the test material. This may be in fact the only population that is sensitive to the test material, and if you don't look at all of those, I think you could miss a relatively weak effect that could be occurring in that subpopulation. I myself, as a pathologist, would feel that all of those animals, rather than a few, should be looked at because the effect's going to be quite weak to begin with. Do you want to answer that?
DR. MC CONNELL: Yes. First of all, maybe I gave the wrong impression. Using this protocol we wouldn't do the histopathology within 14 or 30 days of when they died.
Rather, the early death animals would be examined as part of the 15 month interim evaluation.
DR. WEINBERGER: Okay. Then, I think I misunderstood.
DR. MC CONNELL: Yes. We're going to look at every animal in the study in the high dose and in the controls, although we won't be looking at as many tissues from each animal after 15 months. DR. WEINBERGER: Okay. The other point is that you emphasized how important it is to have a good gross necropsy. But, in fact, in most laboratories, the necropsies, when large -numbers of animals have to be examined, the necropsies are more like an assembly line where you have high numbers of people very rapidly processing animals without the care or the attention and the minute observations that are really needed for careful observations that may have tremendous importance on risk assessment. I think, in fact, in the real situation, that's-simply not going to exist. What you are recommending will not really exist. That being the case, I think that it becomes much more important to look at a large number of tissues. I think that the traditional method (which has been to look at the tissues at the end of two years, look at all the high dose and all the controls, which has worked very well for many pathologists for many, many years) should be discarded without very careful study of whether or not the new method is going to be superior to the old method. It seems to me that the two year target point is a better point, from the point of view of carcinogenicity then looking at animals at 15 months because a great deal can happen between 15 and 24 months. I feel that a better system or one that has at least been proven is the 24 month examination of all of the tissues in the high dose and in the control groups. DR. MC CONNELL: Okay. First of all. 1 would agree that it requires a good necropsy, However, I think that there are a lot of laboratories out there that are performing good necropsies, 1 wouldn't have said that maybe five years ago, but in my experience, one pathologist can monitor four or five technicians conducting the necropsies. It usually takes 40 minutes to do a decent necropsy in an animal (in a mouse or a rat). At this rate even if you have five necropsy technicians, I think any competent pathologist ought to be able to make observations and notes on every one of those animals. I've seen it done in too many laboratories to know that it can be done. What was your other question? DR. WEINBERGER: Well, in a way, I was making comments rather than questions.
DR. MC CONNELL: I was going to make the comment that the 15 month interim evaluation is not for carcinogenicity. However if it gives us a hint of a neoplastic response, that's frosting on the cake. But that's not the object of the 15 month evaluation. The object is to give us good information on chronic toxicity. DR. WEINBERGER: I think that at 24 months, even though you proposed one possible exception, I think by and large, there isn't a great deal of problem in detecting toxicity in the organs at 24 months. As you pointed out in the study of Goodman and Ward, they were able to delineate toxic reactions.
DR. MC CONNELL The data in Goodman's or Ward's papers weren't toxic reactions. They were spontaneous disease (lesions) such as d~generative changes.
DR. WEINBERGER: Well, they were similar to the kinds of reactions one would see in toxic lesions. I simply am saying that toxic effects are frequently related to neoplasia. They are not separate phenomena. They are TOXICOLOGIC PATHOLOGY very closely related, and therefore, looking at them together at 24 months, I think could be advantageous rather than looking at them separately.
DR. MC CONNELL: And we would, because we would have identified the target organ in the 15 month evaluation and that would become one of our "core list" organs in the 24 month evaluation, including the evaluation of chronic toxicity. I think we have chronic toxicity covered in the 24 month evaluation. I just think we are doing it better by looking at animals at 15 months or 1 2 months or whenever, too.
DR. CAMPBELL: You mentioned parameters of clinical pathology. Among the people I work with, they're some jokers who refer to automated biochemical estimations (you know, the SMA-12 type.) Well, one remarked, "It's the greatest source of irrelevant and misleading data in modern medicine". Others refer to this sort of thing as "biochemical bird shot". Not too long ago I heard one say "it was just window dressing for the amusement of administrators". What is the truth, in your opinion?
DR. MC CONNELL: I agree with all three opinions, in the way clinical chemistry is currently being done in many labs. A SMA-1 2 or 18 is a waste of time unless it is geared particularly to the rodent. Unfortunately, in many laboratories, it's geared to human blood using human control reagents, etc. Unless you use rodent blood as your control and the proper standards for your particular machine, the results are questionable. In a lot of laboratories clinical chemistry is probably a waste of time as currently performed. Why not go after those specific clinical chemistry parameters that you think are necessary to answer the question that you want to answer rather than the "shot gun" approach.
DR. de la IGLESIA: I do have a comment which is perhaps a bit philosophical, but it worries me a lot. In the numbers game in America, about having a pathologist reading 50,000 slides per year. I really am concerned because that translates to a lot of slides per day, and I am wondering whether that pathologist is getting to read journals or participate in conferences, or even consult with colleagues. I think it is a very important mission of this symposium to establish-what should be reasonable pathology workload, not in terms of limiting the protocol but in terms of what, practically, should be done.
Secondly, I believe that pathologists should not be "blind coding" slides. If one wants to make an intelligent interpretation of a change in tissue, one really needs the clinical history and gross examination to make an intelligent assessment of the tissue changes. I'd like to propose that some standard of conduct of pathology be built into these protocols so that it's not just X number of tissue times the numbers of organs and times the numbers of animals.
DR. MC CONNELL: I won't comment on your number of slides per year because I'm not sure what is the right number. But, in terms of blind pathology, I think there is a very important place for blind pathology as Dr. Szczech pointed out. That is-once you find a lesion, particularly a subtle lesion, you want to be sure that that is due to the chemical. The only way you find that out is to take those slides containing suspect lesions, mix them up with some controls and see it you can pick out the ones with lesions. If you can't pick the lesion out in those particular animals, or close to 100% of them, I question whether you have a lesion. That's where we use blind pathology, not in the first-go-round.
DR. IATROPOULOS: Really, the presentation was excellent. A lot of new parameters have entered. A lot of proper explanations or reasoning was added. There are a couple of very disturbing instances-one being that there are regulatory agencies that, right now, are really turning down carcingenicity studies that have not reached 27 months. If one is a careful examiner of the survival tables, with the numbers that they suggest, it becomes very obvious that by the 20-21st month, with 50 per group and sex, you are going to be left with very few animals. Can we draw a concensus, being people who really and sincerely want to put biology back into that particular study? I agree with you, whatever you said about the time factor, but how come, for example, alone in the United States, we have two or three different opinions on that particular subject and they are conflicting? Number two, hallmark of neoplasia is the fact that after you take away the stimulus, you still have proliferation. How do you address this particular aspect without any recovery segment because toxicity it obviously "hand in glove" with carcinogenicity? So, how can this be addressed in that very important suggestion that you are making? DR. MC CONNELL: I think that that's the subject of tomorrow. I really would prefer not to talk about "start/stop" studies at this time. I think they have their place, but I don't want to steal someone else's thunder. DR. IATROPOULOS: What's your personal opinion?
DR. MC CONNELL: Of start/stop studies? I think they have their place. We're incorporating them in certain of our studies.
Whether the definition of neoplasia . . . is that if you have a proliferative lesion which doesn't go any further once you withdraw the stimulus is a debatable point. Some people certainly would take your side and I know other investigators who would take the other side.
DR. IATROPOULOS: How about the length of the experiment?
DR. MC CONNELL: I think 24 months is a reasonable time. However, I have done lifetime studies-for instance, the asbestos study I spoke about before. The reason for a lifetime study in that case is that it's been documented very clearly that mesothelioma due to asbestos does not occur until 27-31 months into the study. You should design your study to answer the necessary question. Of course, with asbestos, mesothelioma was a key question. I think, nine times out of ten, 24 months is probably the best time to terminate a study because you lose more than you gain by carrying it on for a lifetime. For example I realize that when I do a lifetime study, if this particular chemical is going to cause an increase in C cell tumors of the thyroid, I'll never be able to determine that because a high incidence will be present in the control group at the end of the study. But, that wasn't the question that we were asking in the asbestos study. It's very important to design the study to the question that you are trying to answer.
DR. BECCI: I think everyone up until now has had a larger breakfast than I have, so I'll be brief. I have two concerns I'm not sure the answers will be forth coming immediately.
DR. MC CONNELL: Can you ask them one at a time?
DR. BECCI: Yes. The first one is concerning organ weights. We have touched on clinical pathology. I'm concerned about the quality of organ weight data. Generally, I'm not happy with the way we get it at our place either. The precision of the actual determination-how you trim, whether you take the blood out, all of that stuff. There's a big variability. That's one problem. The next question is-can we standardize that procedure among all of us to preserve the histology. If we're going to take parathyroids, for example, by the time we get through trimming it and weighing it and then you go to look at it, you can't tell what's going on. Can everyone agree perhaps to fix the tissue first and then trim and weigh and do fixed tissues and weights, or does that have a scientific reason where it invalidates the thing? I need help in that area.
DR. MC CONNELL: That's exactly the way we do it, Tom.
DR. BECCI: But, everybody doesn't. DR. MC CONNELL: I see. Are you proposing that somebody needs to sit down and set up the criteria? DR. BECCI: Anything would help. We're being blind in that area, I think. The other one has to do with the cause of death determination. I've had long arguments with David Gailord at NCTR and others. We have a different point of view about that. I recognize the need, but I'm troubled because in my own experience and maybe it relates to only certain cases, I can take 24 month old Fischer rats; they have mononuclear cell leukemia, they have advanced nephropathology, they have multiple endocrine involvements. One of those animals dies, say at 21 months or a week before 24 months, and I have to make a cause of death determination. If it has these complexes, I'll say mononuclear cell leukemia. If it comes to termination necropsy and has the same complex including his leukemia with anemia, it's a terminated case, I don't have to make a cause of death determination. Yet, when I take ten of these and ten of those, and I've done that, and I mix them together, I can't separate which ones died spontaneously and which ones were killed because they look the same to me. Yet, on the one hand, I'm making decisions and he's using them statistically and on the other hand, they are different. It's just a consideration.
DR. MC CONNELL: Except that I think those rats with Fischer rat leukemia that you saw at 24 months would have died if they lived a week or two longer. DR. BECCI: Well, that's not the question. They would be counted as neoplasms for sure, but.. . .
DR. MC CONNELL: But if they died one
week before the end of the study, in the life-table analysis, they're not given much importance in the sense that it only subtracts one week in terms of probability.
DR. BECCI: Twenty-one months is going to be alright? DR. MC CONNELL: Twenty-one months doesn't add that much in terms of life-table analysis. It's the earlier deaths (+-I2 months) that really affect this statistical exercise.
DR. BECCI: Okay. That was the only other point that I had.
DR. MC CONNELL: You may want to talk to a statistician to see how early deaths impact on the interpretation of a given type of neoplasm.
DR. DAWES: I agree entirely with your comments on elderly rats and the arguments for the 15 month kill. There's just one thing that worries me about this. At the beginning of the experiment, we plan it. When you plan a toxicity study, you'll have a different criteria for choosing your dose levels to the planning of a carcinogenicity study. I'm afraid that by having this 15 month possibility, you've got to be very, very careful to discipline yourself to say this is a carcino: genicity study, not a toxicology study. That's the only thing that worries me. I agree entirely though with your reasons for having the kill at that time.
DR. MC CONNELL: If you have a three dose study, would you choose three different doses for the chronic toxicity study then for the carcinogenesis study? Is that what you are proposing? DR. DAWES: Yes. I think my top dose certainly would be higher in a chronic toxicity one.
DR. MC CONNELL: By definition, our highest dose for a carcinogenicity study is the highest possible dose that will not reduce survival of that group by more than ten per cent due to non-tumor lesions. You'd have a dose even higher than that? DR. DAWES: Yes, if I killed half my animals in the course of the study in the top dose.
DR. MC CONNELL: But wouldn't you do that in a study of shorter duration? Maybe we have a different definition of chronic toxicity.
DR. DAWES: Yes. Can I come to my second point? That is, when we're looking at tumors, we tend to have quite low numbers of tumors which can be statistically very, very significant. I was thinking rather in the analogy of a LD-50 where quite often you get more animals dying in one of the lower doses than at the top dose you have given. This is well known, and there are mathematical ways of sorting it out. But, what my plea would beif you're not doing full histology on your intermediate doses, at least look very, very carefully at autopsy. You could get a situation, not because of any of the strange mechanisms we've talked about today, just by statistical chance, although you're getting dose relation increase in tumors, your middle dose and top dose have reversed their numbers. This is very, very common with short-term tests.
DR. MC CONNELL: In short-term? DR. DAWES: Yes. This sort of appearance and with the small numbers-no tumors of a particular kind in a control group out of 50, four or five out of 50 in your top dose. That's very significant.
DR. MC CONNELL: We find a higher incidence of tumors in the low dose versus the high dose group to be a very rare event in a two year study based on those 287 studies in our data base. In such a case, if the animals survived and everything went well in the study, we would probably call that a spurious observation and wouldn't call that chemical a carcinogen. At most we would say that there was "equivocal" evidence of carcinogenicity in such a case. DR. DAWES: I was thinking more of a case where you had multiply dose levels and it just happened that the top dose was the one that escaped.
